公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2009 | HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during Adefovir dipivoxil therapy | Tseng K.-C.; Cheng P.-N.; Wu I.-C.; CHIN-KUO CHANG ; Chou A.-L.; Liu W.-C.; Chang T.-T. | Hepato-Gastroenterology | 5 | 5 | |
2015 | HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients | Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; TUNG-HUNG SU ; TAI-CHUNG TSENG ; Lin H.H.; Wang C.-C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 12 | 11 | |
2021 | Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort) | Hsu W.-F.; Tsai P.-C.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. | Journal of Gastroenterology and Hepatology (Australia) | 7 | 10 | |
2012 | HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin | Tseng C.-W.; Hsieh Y.-H.; CHIN-KUO CHANG ; Lai N.-S.; Hung T.-H.; Wu S.-F.; Tseng K.-C. | Tissue Antigens | 2 | 1 | |
2021 | The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma | Wang C.-C.; Tseng K.-C.; Tzeng I.-S.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 7 | 6 | |
2022 | Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR) | Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; SHIH-JER HSU ; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. | Clinical Gastroenterology and Hepatology | 14 | 12 | |
2010 | The impact of the chi-chi earthquake on the incidence of hospitalizations for schizophrenia and on concomitant hospital choice | Tseng K.-C.; Hemenway D.; Kawachi I.; Subramanian S.V.; WEI J. CHEN | Community Mental Health Journal | 10 | 13 | |
2015 | Isolation and identification of post-transcriptional gene silencing-related micro-RNAs by functionalized silicon nanowire field-effect transistor | Chen K.-I.; Pan C.-Y.; Li K.-H.; Huang Y.-C.; Lu C.-W.; Tang C.-Y.; Su Y.-W.; Tseng L.-W.; Tseng K.-C.; Lin C.-Y.; Chen C.-D.; Lin S.-S.; YIT-TSONG CHEN ; SHIH-SHUN LIN ; CHIEN-YUAN PAN | Scientific Reports | 6 | 5 | |
2022 | Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan | Lo C.-C.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Chen C.-Y.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; Chuang W.-L.; Lin H.-C.; JIA-HORNG KAO ; Yu M.-L.; TACR investigators | Journal of the Formosan Medical Association | 3 | 0 | |
2020 | Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C | CHUN-JEN LIU ; Tseng K.-C.; Lo C.-C.; Tseng I.-H.; Cheng P.-N. | Journal of the Formosan Medical Association | 3 | 2 | |
2021 | Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) | Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; CHUN-JEN LIU ; Yu M.-L. | Hepatology International | 4 | 5 | |
2021 | Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan | Hsieh M.-H.; Bair M.-J.; Tsai P.-C.; Tseng K.-C.; Lo C.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Yu M.-L.; Chuang W.-L.; T-COACH investigators | Journal of Gastroenterology and Hepatology (Australia) | 2 | 3 | |
2021 | Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan | Huang C.-F.; Kuo H.-T.; Chang T.-S.; Lo C.-C.; Hung C.-H.; Huang C.-W.; Chong L.-W.; Cheng P.-N.; Yeh M.-L.; Peng C.-Y.; Cheng C.-Y.; Huang J.-F.; Bair M.-J.; Lin C.-L.; Yang C.-C.; Wang S.-J.; Hsieh T.-Y.; Lee T.-H.; Lee P.-L.; Wu W.-C.; Lin C.-L.; Su W.-W.; Yang S.-S.; Wang C.-C.; Hu J.-T.; Mo L.-R.; Chen C.-T.; Huang Y.-H.; Chang C.-C.; Huang C.-S.; Chen G.-Y.; Kao C.-N.; Tai C.-M.; CHUN-JEN LIU ; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; JIA-HORNG KAO ; Lin H.-C.; Chuang W.-L.; Chen C.-Y.; Tseng K.-C.; Yu M.-L. | Scientific Reports | 9 | 5 | |
2010 | Prognostic effect of human leukocyte antigen class I and II alleles on chronic hepatitis C patients treated by pegylated interferon-alfa plus ribavirin in Taiwan | Tseng K.-C.; CHIN-KUO CHANG ; Chou A.-L.; Hsieh Y.-H.; Tseng C.-A.; Lai N.-S. | Hepato-Gastroenterology | 10 | 7 | |
2015 | Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients | Yang C.-C.; Tsai W.-L.; Su W.-W.; Huang C.-F.; Cheng P.-N.; Lo C.-C.; Tseng K.-C.; Mo L.-R.; Wang C.-H.; SHIH-JER HSU ; Lai H.-C.; Su C.-W.; CHUN-JEN LIU ; Peng C.-Y.; Yu M.-L. | PLoS ONE | 8 | 5 | |
2009 | Rhabdomyolysis following dose increase of clozapine and combination therapy with lithium | Tseng K.-C.; TZUNG-JENG HWANG | Journal of Clinical Psychopharmacology | 15 | 11 | |
2020 | Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B | Huang Y.-W.; Hsu C.-W.; Lu S.-N.; Yu M.-L.; Su C.-W.; Su W.-W.; Chien R.-N.; Hsu C.-S.; SHIH-JER HSU ; Lai H.-C.; Qin A.; Tseng K.-C.; PEI-JER CHEN | Hepatology International | 18 | 14 | |
2021 | Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy | Lin H.-H.; SHIH-JER HSU ; Lu S.-N.; Chuang W.-L.; Hsu C.-W.; Chien R.-N.; Yang S.-S.; Su W.-W.; Wu J.-C.; Lee T.-H.; Peng C.-Y.; Tseng K.-C.; Qin A.; Huang Y.-W.; PEI-JER CHEN | JGH Open | 12 | 12 | |
2022 | Skillful Seasonal Prediction of North American Summertime Heat Extremes | Jia L; DELWORTH T.L; Kapnick S; Yang X; JOHNSON N.C; Cooke W; Lu F; Harrison M; Rosati A; Zeng F; Mchugh C; WITTENBERG A.T; Zhang L; Murakami H; Tseng K.-C.; KAI-CHIH TSENG | Journal of Climate | 5 | 3 | |
2022 | Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan | Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; CHUN-JEN LIU ; Dai C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L.; Yu M.-L.; TACR investigators | Infectious Diseases and Therapy | 9 | 8 |